Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions

Cancers

Abigail T. Berman²  Sara St. James¹  Ramesh Rengan¹ 

[1] Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA; E-Mails:;Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA

关键词: lung cancer;    radiotherapy;    re-irradiation;    proton beam therapy (PBT);    post-operative radiation therapy (PORT);   

DOI  :  10.3390/cancers7030831

来源: mdpi

【 摘 要 】

Lung cancer is the leading cancer cause of death in the United States. Radiotherapy is an essential component of the definitive treatment of early-stage and locally-advanced lung cancer, and the palliative treatment of metastatic lung cancer. Proton beam therapy (PBT), through its characteristic Bragg peak, has the potential to decrease the toxicity of radiotherapy, and, subsequently improve the therapeutic ratio. Herein, we provide a primer on the physics of proton beam therapy for lung cancer, present the existing data in early-stage and locally-advanced non-small cell lung cancer (NSCLC), as well as in special situations such as re-irradiation and post-operative radiation therapy. We then present the technical challenges, such as anatomic changes and motion management, and future directions for PBT in lung cancer, including pencil beam scanning.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.